USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Acorda Therapeutics, Inc.
Address:
15 Skyline Drive
Hawthorne, NY 10532
Phone:
(914) 347-4300
URL:
N/A
EIN:
133831168
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,040,363.00 8
STTR Phase I $295,521.00 3
STTR Phase II $980,125.00 1

Award List:

4-AP THERAPY OF CHRONIC PAIN AND SPINAL INJURY

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$99,662.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

PROMOTION OF NERVE REGENERATION BY FRAGMENTS OF L1

Award Year / Program / Phase:
1999 / STTR / Phase I
Award Amount:
$99,995.00
Agency:
HHS
Principal Investigator:
Grumet
Research Institution:
New York University Medical Center
RI Contact:
N/A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Timothy J. Neuberger
Abstract:
Not Available If the development of a vehicle capable of sustained hypersonic flight in the atmosphere at speeds above Mach 8 is to be realized, a ground-based wind tunnel with a reliable force measurement system is a necessity. However, above Mach 8, due to thermal s

N/A

Award Year / Program / Phase:
2000 / STTR / Phase I
Award Amount:
$195,526.00
Agency:
HHS
Principal Investigator:
Moses Rodriquez, Principal Investigator
Research Institution:
Mayo Clinic
RI Contact:
N/A
Abstract:
N/a

Antisense Technology for Neural Protection and Repair

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$139,371.00
Agency:
HHS
Principal Investigator:
Magdalena Hofer
Abstract:
Spinal Cord Injury (SCI) is a devastating condition for which there is no effective treatment. The cost to society is enormous because most new cases occur in people under the age of 30 and these individuals have a near normal life expectancy. Therefore, the development of a new, effective therapy… More

Tenascin-C-Fragments for Spinal Cord Regeneration

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Andrew R. Blight
Abstract:
The goal of this project is to conduct pre-clinical tests of components of the extracellular matrix molecule tenascin-C that offer potential as therapeutics for enhancing nerve fiber regeneration. This may lead to the development of a treatment for spinal cord injury, a… More

HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION

Award Year / Program / Phase:
2002 / STTR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Research Institution:
MAYO FOUNDATION
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimulate remyelination to further develop for clinical testing in inflammatory demyelinating disease, such… More

Release Chondroitinase Systems for Spinal Cord Injury

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$107,300.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and causes a severe and debilitating condition in the individual. Following SCI, limited regeneration of injured neurons results in permanent disability characterized… More

Molecular Evolution of Chondroitinase ABCI for SCI

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$184,388.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Spinal cord injury (SCI) is a devastating event affecting approximately 11,000 individuals each year in the US alone. Although most victims survive, the individual is often paralyzed for the rest of his or her life. Sixty percent of injuries occur in individuals… More

Effects of Chondroitinase and Training in Acute SCI

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$156,491.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and typically results in debilitating loss of function below the level of injury, for which no effective treatment exists. Chondroitin Sulfate Proteoglycans (CSPGs)… More

Chimeric proteins for the treatment of spinal cord injury

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$153,151.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and causes a severe and debilitating condition in the individual. Following SCI, limited regeneration of injured neurons results in permanent disability characterized… More